Levodopa + Carbidopa + Entacapona Ciclum

Levodopa, the active ingredient in Levodopa + Carbidopa + Entacapona Ciclum, is a dopamine precursor presented as an oral tablet for oral administration. It is combined with carbidopa and entacapone to improve motor symptoms in adults with Parkinson's disease.

GNH USA supplies Levodopa + Carbidopa + Entacapona Ciclum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets.

Levodopa/Carbidopa/Entacapone is indicated for the management of Parkinson's disease, a neurodegenerative disorder affecting dopaminergic pathways.

- Parkinson's disease (early stage): improves motor symptoms such as bradykinesia, rigidity and tremor. - Parkinson's disease (advanced stage with motor fluctuations): reduces OFF time and prolongs ON periods when used with levodopa. - Parkinson's disease (adjunct therapy): enhances overall efficacy of levodopa by increasing its central availability.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: sensation of light‑headedness, especially on standing. - Dry mouth: reduced salivation causing discomfort. - Insomnia: difficulty initiating or maintaining sleep. - Orthostatic hypotension: drop in blood pressure upon standing. - Dyskinesia: involuntary movements, often dose‑related.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and rigidity. - Severe psychiatric disturbances: hallucinations, delusions or worsening psychosis. - Cardiac arrhythmias: uncommon but may occur with pre‑existing heart conditions. - Severe hypotension: marked blood pressure decline requiring medical attention. - Allergic reactions: rash, pruritus or anaphylaxis in susceptible individuals.

When prescribing Levodopa/Carbidopa/Entacapone, clinicians should consider several safety measures.

- Dose titration: adjust gradually based on clinical response and tolerability. - Cardiovascular monitoring: observe for orthostatic hypotension and arrhythmias. - Psychiatric assessment: monitor for hallucinations, confusion or mood changes. - Renal/hepatic function: evaluate before initiation and adjust if impairment is present. - Drug interactions: review concomitant medications for potential major or moderate interactions. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Levodopa/Carbidopa/Entacapone can interact with several medicines; interactions are categorized by clinical significance.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: may cause hypertensive crisis when combined. - Antipsychotics with strong dopamine blockade: can markedly reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Iron or vitamin C supplements: may decrease levodopa absorption; separate dosing by at least 2 hours. - Antihypertensive agents: additive blood‑pressure‑lowering effect may require dose adjustment. - SSRIs or SNRIs: may increase risk of serotonin syndrome, requiring careful monitoring.